New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:19 EDTCGIXCGI announces collaborative study results on kidney cancer microarray test
Cancer Genetics announced the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. Cancer Genetics is currently commercializing the test nationally by making it available as laboratory developed test. This study and final data were presented this week by Dr. Magi-Galluzzi of the Cleveland Clinic at a podium presentation at the 2014 United States & Canadian Academy of Pathology annual meeting in San Diego. These results provide additional evidence to support the clinical value of CGI's, unique, disease-focused, genomic tests.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
07:32 EDTCGIXCancer Genetics to receive $530,000 through NJ Technology Business Tax Program
Cancer Genetics announced that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
December 8, 2014
07:37 EDTCGIXCancer Genetics announces launch of sequencing based panel for CLL
Cancer Genetics announced it has been licensed by the Clinical Laboratory Improvement Amendments to perform Focus::CLL, the company's unique next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma. The panel assesses seven genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use